How much funding has Sironax raised?

Sironax has raised $200.0M in total funding, most recently a Series B round.

Who are Sironax's investors?

Sironax's investors include Gaorong Capital, Yunfeng Capital, Temasek, Invus, F-Prime Capital, ARCH Venture Partners.

Where is Sironax headquartered?

Sironax is headquartered in Beijing, China.

What industry is Sironax in?

Sironax operates in Biotech, Healthcare.

Sironax

Transformative therapies for degenerative diseases

Beijing, China · Founded 2017 · $200.0M raised

Biotech

Healthcare

Headquarters: Beijing
Employees: 51–200
Founded: 2017
Business Model: B2B

Website: sironax.com
Total Funding: $200.0M
Last Round: $200.0M Series BAug 2022
Rounds: 1

About

Sironax is a clinical-stage biotechnology company founded in 2017 by Dr. Xiaodong Wang and Dr. Zhiyuan Zhang, targeting neurodegenerative, inflammatory, metabolic, and rare diseases. The company is advancing three clinical candidates—SIR2501, SIR9900, and SIR4156—with 170+ employees across the US, China, Switzerland, and Australia. In 2025, Sironax granted Novartis an exclusive option to acquire its Brain Delivery Platform.

Summary

Sironax is a Biotech company based in Beijing, China, founded in 2017. It has raised $200.0M in total across 1 round, most recently a $200.0M Series B round in Aug 2022. Investors include Gaorong Capital, Yunfeng Capital and Temasek.

LinkedIn X (Twitter)